Nasal insulin plus glutathione for Parkinson’s symptoms
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This Phase 2 study tests whether adding nasal insulin and glutathione can improve Parkinson’s disease symptoms and function. You would use study medicine through the nose while keeping your other treatments mostly the same during the trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of Parkinson’s disease that is “idiopathic” (not caused by another condition).
- You can give the nasal study medicine yourself or have a caregiver who can help for the whole study.
- You can keep your diet, exercise, and Parkinson’s medications mostly the same throughout the study (with only essential changes allowed).
- If you take Parkinson’s medicines or supplements, your dose must have been stable for at least 30 days before screening.
- If you take antidepressants or anti-anxiety medicines, your dose must have been stable for at least 90 days before screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new nasal spray called XJN010 for people with Parkinson's who have 'off' episodes—times when their regular medication wears off and symptoms come back. The goal is to see if the spray can safely and effectively help during those periods.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
This trial tests if a low dose of carbon monoxide (HBI-002) is safe and helpful for people with Parkinson's disease. It requires specific health criteria and stable Parkinson's medication.
This trial tests whether the anti-inflammatory drug dapansutrile can help people with early Parkinson's disease. You would get either dapansutrile or a placebo (a pill with no active drug) to see if it slows the disease.
This trial tests whether sitagliptin, a diabetes drug, can slow the progression of early Parkinson's disease. It aims to see if the medication can protect brain cells and reduce symptoms, potentially offering a new way to treat Parkinson's.
Hear when a new Parkinson Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.